Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III)

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3588-3595

  Schmoll, Hans Joachim ^a   Cunningham, David ^b   Sobrero, Alberto ^d   Karapetis, Christos S ^e   Rougier, Philippe ^g   Koski, Sheryl L ^h   Kocakova, Ilona ⁱ   Bondarenko, Igor ^j   Bodoky, György ^k   Mainwaring, Paul ^f   Salazar, Ramon ^l   Barker, Peter ^c   Mookerjee, Bijoyesh ^c   Robertson, Jane ^c   Van Cutsem, Eric ^m  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

^e FLINDERS UNIVERSITY   (Australia)

^f Hematology and Oncology Clinics of Australia   (Australia)

^g HÔPITAL AMBROISE PARÉ   (France)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^j City General Hospital   (Ukraine)

^k St László Teaching Hospital   (Hungary)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867115561     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.5355     Document Type: Article

References (33)

1. Schmoll HJ, Van Cutsem E, Stein A: ESMO consensus guidelines for management of patients with colon and rectal cancer: A personalized clinical decision making. Ann Oncol (in press)
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
3. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005
4. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
5. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005 (Pubitemid 40775678)
6. Drevs J, Medinger M, Mross K, et al: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23:192s, 2005 (suppl 16; abstr 3002)
7. Batchelor TT, Duda DG, di Tomaso E, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010
8. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007 (Pubitemid 47218051)
9. Matulonis UA, Berlin S, Ivy P, et al: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601-5606, 2009
10. Yamamoto N, Tamura T, Yamamoto N, et al: Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 64:1165-1172, 2009
11. Laurie SA, Gauthier I, Arnold A, et al: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26:1871-1878, 2008
12. Chen E, Jonker D, Gauthier I, et al: Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 15:1481-1486, 2009
13. Goss G, Shepherd FA, Laurie S, et al: A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 45:782-788, 2009
14. Goss GD, Arnold A, Shepherd FA, et al: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28:49-55, 2010
15. Lorusso P, Shields AF, Gadgeel S, et al: Cediranib in combination with various anticancer regimens: Results of a phase I multi-cohort study. Invest New Drugs 29:1395-1405, 2011
16. van Cruijsen H, Voest EE, Punt CJ, et al: Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 46:901-911, 2010
17. Hoff PM, Hochhaus A, Pestalozzi B, et al: Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (MCRC): A randomized, double-blind, Phase III study (HORIZON II). Ann Oncol 21:viii9, 2010 (suppl 8; abstr LBA19) 17a.
18. Hoff PM, Hochhaus A, Pestalozzi BC, et al: Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30:3588-3595, 2012
19. AstraZeneca: Global policy: Bioethics, 2011. http://www.astrazeneca.com/ Responsibility/Code-policies-standards
20. Köhne CH, Cunningham D, Di Costanzo F, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 13:308-317, 2002 (Pubitemid 34704985)
21. Whitehead J: The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med 8:1439-1454, 1989
22. Ellis S, Carroll KJ, Pemberton K: Analysis of duration of response in oncology trials. Contemp Clin Trials 29:456-465, 2008
23. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
24. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
25. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 26:3523-3529, 2008
26. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
27. Schutz FA, Je Y, Choueiri TK: Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Crit Rev Oncol Hematol 80:291-300, 2011
28. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al: Final results from a randomized, double-blind, Phase III study of sunitinib plus FOLFIRI vs. placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Ann Oncol 21:vi19, 2010 (suppl 6; abstr O-0026)
29. Brave SR, Ratcliffe K, Wilson Z, et al: Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Mol Cancer Ther 10:861-873, 2011
30. Van Cutsem E, Tabernero J, Lakomy R, et al: Intravenous (iv) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational Phase III TRIAL (EFC10262-VELOUR). Ann Oncol 22:vi8, 2011 (suppl 5; abstr O-0024)
31. Van Cutsem E, Prenen H, Guillen-Ponce C, et al: A Phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer. Eur J Cancer 47:8-9, 2011 (suppl 2)
32. Van Cutsem E, Sobrero AF, Siena S, et al: Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 30:203s, 2012 (suppl 15; abstr 3502)
33. Schmoll H, Hoff PM, Robertson JD, et al: Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC). J Clin Oncol 29:243s, 2011 (suppl; abstr 3590)